Catalyst Pharma director equity canceled in merger
Catalyst Pharmaceuticals director Tamar Thompson reported the disposition of all reported equity positions in connection with the acquisition of Catalyst Pharmaceuticals, Inc. by Angelini Pharma S.p.A.
Rhea-AI Filing Summary
Catalyst Pharmaceuticals director Tamar Thompson reported the disposition of all reported equity positions in connection with the acquisition of Catalyst Pharmaceuticals, Inc. by Angelini Pharma S.p.A. On 2026-07-15, 3,773 shares of common stock were surrendered at $31.50 per share, and multiple restricted stock unit and stock option awards covering specified shares were cancelled and converted into cash based on the $31.50 per-share merger price. Following these transactions, the reported holdings show 0 shares and 0 derivative awards remaining for the positions covered.
Positive
- None.
Negative
- None.
Insider Trade Summary
Disposition: 123,436 shares
Disposition
8 txns
Insider
Thompson Tamar
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 40,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 29,524 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 23,248 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 18,115 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 1,414 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 1,894 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 5,468 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 3,773 | $31.50 | $119K |
Holdings After Transaction:
Options to purchase common stock — 0 contracts (Direct);
Restricted Stock Units — 0 contracts (Direct);
Common Stock, par value $0.001 per share — 0 shares (Direct)
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Common shares disposed: 3773 shares
RSUs cancelled (2028-11-20 expiry): 5468 units
RSUs cancelled (2027-11-21 expiry): 1894 units
+5 more
8 metrics
Common shares disposed
3773 shares
Common stock surrendered at $31.50 per share on 2026-07-15 in connection with the merger
RSUs cancelled (2028-11-20 expiry)
5468 units
Restricted stock units cancelled and converted to cash at a $31.50 per-share basis
RSUs cancelled (2027-11-21 expiry)
1894 units
Restricted stock units cancelled and converted to cash at a $31.50 per-share basis
RSUs cancelled (2026-12-08 expiry)
1414 units
Restricted stock units cancelled and converted to cash at a $31.50 per-share basis
Options cancelled at $22.77 strike
18115 options
Options to purchase common stock cancelled; cash based on $31.50 less $22.77 per-share exercise price
Options cancelled at $21.12 strike
23248 options
Options to purchase common stock cancelled; cash based on $31.50 less $21.12 per-share exercise price
Options cancelled at $14.15 strike
29524 options
Options to purchase common stock cancelled; cash based on $31.50 less $14.15 per-share exercise price
Options cancelled at $11.60 strike
40000 options
Options to purchase common stock cancelled; cash based on $31.50 less $11.60 per-share exercise price
Key Terms
restricted stock unit, stock option, per-share price, tax withholdings, +1 more
5 terms
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
tax withholdings financial
"cash payment (without interest, and less applicable tax withholdings and other authorized deductions)"
Merger regulatory
"disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
FAQ
What insider transaction did Catalyst Pharmaceuticals (CPRX) director Tamar Thompson report?
Tamar Thompson reported disposing of all reported equity positions in Catalyst Pharmaceuticals on 2026-07-15. Common shares, RSUs, and stock options were surrendered or cancelled and converted into cash in connection with the $31.50 per-share acquisition by Angelini Pharma S.p.A.
What happened to Tamar Thompson’s restricted stock units in Catalyst Pharmaceuticals (CPRX)?
Reported restricted stock units were cancelled and converted into cash tied to a $31.50 per-share value. Each RSU became a right to receive a cash payment equal to $31.50 multiplied by the number of RSU shares, less applicable tax withholdings and deductions.
How were Tamar Thompson’s Catalyst Pharmaceuticals (CPRX) stock options treated in the merger?
Each reported stock option was cancelled and converted into cash equal to ($31.50 minus the option’s exercise price) times the option shares. Footnotes state the options were fully vested or vested in full upon consummation of the Angelini Pharma S.p.A. merger.
Did Tamar Thompson retain any Catalyst Pharmaceuticals (CPRX) equity after the Angelini merger?
For the positions reported, the Form 4 shows 0 shares of common stock and 0 derivative awards remaining after the 2026-07-15 transactions. All listed common shares, RSUs, and stock options were disposed of or cancelled in connection with the acquisition by Angelini Pharma S.p.A.
Was Tamar Thompson’s Catalyst Pharmaceuticals (CPRX) Form 4 filed under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan. Footnotes instead emphasize that the dispositions and cancellations occurred in connection with the consummation of the Angelini Pharma S.p.A. merger at $31.50 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
